← Previous · All Episodes · Next →
Will There Be a Universal Cure for Sickle Cell Disease? Episode 9

Will There Be a Universal Cure for Sickle Cell Disease?

Today's episode is about gene therapy, stem cells, and bone marrow transplants. Dr. Scott and Dr. Kieffer provide a basic framework of sickle cell and gene therapy and how they differ from a bone marrow transplant. Tune in and listen to the full episode.

· 53:36

|
Today's show is brought to you by the Essential RX segment with Dr. Lametra Scott. The VitaminSC3 Podcast is powered by the Sickle Cell Community Consortium. 

Dr. Ted Kieffer is an American Board of Pathology certified Clinical Pathologist and Transfusion Medicine specialist with specialized training in Clinical Microbiology. He received his medical school, residency, and fellowship training at Indiana University and Indiana University Hospitals pathology program. Dr.Kieffer has worked in medical reimbursement as a senior Healthcare consultant, an associate professor and medical director with West Virginia University and hospital systems, and Cell and Gene Therapy Medical director with a local Tennessee non-profit blood center. He is engaged in several national and international societies and currently sits on the BSR/PDA apheresis collection for cell and gene therapy products standards committee, the intenational society for cell and gene therapy's laboratory professionals committee, and was recently offered the appointment to the TN state Board of Medical Laborator as a Pathologist representative. 

When Where There Be a Universal Cure to Sickle Cell Disease?

Today's episode is about gene therapy, stem cells, and bone marrow transplants. Today's show will provide a basic framework of sickle cell and gene therapy and how they differ from a bone marrow transplant. 

Today's Topic: Is a Universal Cure to Sickle Cell Disease on the Horizon?

  • Dr. Kieffer explains what happens during a bone marrow transplant and how it is different than gene therapy on a pathologic level: Timestamp 06:38

  • Explain the term Myeloablative. Timestamp 10:27
Myeloablative HSCT is the more stringent type of treatment. HSCT destroys the body's (autoreactive) lymphocytes and the bone marrow (source).

  • Where are we in curative therapies, and how are they different from the bone marrow transplant process? Timestamp 13:43

  • Gene editing vs. LentiGlobin Gene Therapy. Timestamp 21:12

  • Curative Therapies are usually only offered to sickle cell patients in dire conditions. Why isn't it provided to more patients sooner? Timestamp 27:00
Tweet able quote: "Healthcare has to be a dialog, it has to be ownership by the treating team." - Ted Kieffer

Follow Dr. Ted Kieffer:
You are more than welcome to connect with Dr. Ted Kieffer to learn more about his research within the sickle cell community
Follow our guest Dr. Lametra Scott:
Donate:
Did you enjoy listening to this episode? If so, please consider donating to keep this podcast going. Donations are tax deductible and are made to the Sickle Cell Community Consortium. 

The next episode of the Vitamin SC3 Podcast drops on Monday
Please tune in next week for a new episode we will hear from the segment Self-care is Healthcare with Dr. Marjorie Brewer. 

Do you Want to Become a Sickle Cell Consortium Partner?
Become a Sickle Cell Community Consortium member by clicking here to learn more.
Follow their  Instagram and Facebook pages to learn more about the Sickle Cell Community Consortium. 



Subscribe

Listen to Vitamin SC3 using one of many popular podcasting apps or directories.

Spotify Google Podcasts Amazon Music
← Previous · All Episodes · Next →